Genomic Vision Announces Early Access Program for a New Detection Suite Based on Innovative Artificial Intelligence Technology Genomic Vision (the "Company" FR0011799907 GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced that it has initiated an early access program for FiberSmart, a new suite to automate the detection and quantification of fluorescent signals on combed DNA. Through innovations in imaging, machine learning and Artificial Intelligence (AI), FiberSmart significantly enhances the automated signal detection, segmentation, and classification with 90% detection sensitivity per coverslip in the Replication Combing Assay (RCA) and 97% sensitivity for Facioscapulohumeral muscular dystrophy (FSHD) assay.